Perimenopause begins when the ovaries start producing less estrogen and progesterone, years before periods stop entirely. The average age at which it starts is 47, though it can begin as early as the mid-30s for some women. The menopausal transition, the full period from first hormonal changes to 12 months after the last period, lasts an average of four to eight years. Menopause itself is defined retroactively: a woman is in menopause when she has gone 12 consecutive months without a period.
Understanding what hormonal changes drive each symptom helps clarify why different symptoms predominate at different stages and why treatment options vary.
The Hormonal Timeline
Perimenopause proceeds through two distinct phases with different hormonal profiles.
Early perimenopause: Estradiol (the primary form of estrogen during reproductive years) fluctuates erratically rather than declining steadily. Follicle development in the ovaries becomes less predictable, producing irregular estrogen peaks that can actually exceed premenopausal levels at times, alternating with lower-than-normal levels. This estrogen variability, not just estrogen deficiency, drives many early perimenopausal symptoms. Progesterone falls more consistently in early perimenopause because ovulation becomes intermittent, and progesterone is produced primarily after ovulation.
Late perimenopause: As ovarian follicle reserves become depleted, both estrogen and progesterone fall more consistently and periods become increasingly irregular. This phase typically begins 1-3 years before the final menstrual period and is when vasomotor symptoms (hot flashes, night sweats) are most intense.
Symptom by Stage
Cycle changes: The first sign for most women is irregular cycle length. Cycles may become shorter (due to accelerated follicle development as FSH rises trying to compensate for declining ovarian response) or longer (due to missed ovulations). Heavier periods can occur in early perimenopause due to an estrogen-dominant state without adequate progesterone opposition.
Hot flashes and night sweats: These vasomotor symptoms occur because declining estrogen affects the hypothalamic thermostat, the set point for body temperature regulation becomes unstable, causing the body to interpret normal temperatures as too hot and trigger heat-dissipating responses (vasodilation, sweating). Approximately 75-80% of women in the menopause transition experience hot flashes. Intensity and frequency vary from occasional mild warmth to frequent, severe episodes that disrupt sleep and daily function.
Sleep disruption: Poor sleep in perimenopause has two distinct causes. Night sweats wake women from sleep directly. Additionally, estrogen and progesterone have direct effects on sleep architecture, both promote sleep quality, and their decline impairs sleep independently of night sweats. Women who do not experience significant hot flashes still often report worsened sleep quality in perimenopause.
Mood changes: Estrogen influences serotonin and dopamine signaling. Periods of rapid estrogen fluctuation, more common in early perimenopause than in postmenopause, correlate with increased rates of depressive symptoms, anxiety, and irritability. Women with a history of premenstrual mood symptoms are more susceptible to perimenopause-related mood changes. This is distinct from clinical depression and often does not require the same treatment approach.
Vaginal and urinary changes: Genital and urinary tissues contain abundant estrogen receptors. As estrogen falls, vaginal tissue becomes thinner and less elastic, with reduced lubrication. Symptoms include vaginal dryness, discomfort during sex, and urinary urgency or frequency. These symptoms are collectively called genitourinary syndrome of menopause (GSM) and are present in approximately 50% of postmenopausal women but underreported and undertreated.
Cognitive changes: Many women report memory lapses and difficulty concentrating in perimenopause. Research from the Study of Women’s Health Across the Nation (SWAN) documented cognitive processing changes during the menopausal transition that generally improve after menopause is established. These are not signs of dementia and typically resolve.
Hair Changes
Estrogen prolongs the hair growth phase. As estrogen declines, the hair cycle shortens and the proportion of hairs in the resting/shedding phase increases. Women in perimenopause and postmenopause commonly notice thinning at the crown and overall reduced density, a pattern that can resemble female pattern hair loss but is driven more by the hormonal shift than by the androgen-sensitivity mechanism. The full discussion of women’s hair loss by cause is in Why Women Lose Hair: The 6 Most Common Causes and What Helps.
Treatment Options
Hormone replacement therapy (HRT): The most effective treatment for vasomotor symptoms and GSM. Current evidence, particularly from the Women’s Health Initiative reanalysis and more recent data, shows that HRT started within 10 years of menopause or before age 60 has a favorable benefit-risk profile for most women without contraindications. The risks that generated concern from the original WHI study were concentrated in older women who started HRT more than 10 years after menopause.
Non-hormonal options for hot flashes: Low-dose SSRIs/SNRIs (particularly paroxetine, venlafaxine), gabapentin, and oxybutynin have evidence for reducing hot flash frequency and severity in women who cannot or prefer not to use HRT. Fezolinetant, a neurokinin-3 receptor antagonist, received FDA approval in 2023 specifically for moderate-to-severe vasomotor symptoms.
Local vaginal estrogen: For GSM without systemic symptoms, low-dose vaginal estrogen (cream, ring, or tablet) produces local tissue effects with minimal systemic absorption, making it appropriate for women with contraindications to systemic HRT.
